https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54994 Wed 27 Mar 2024 16:38:54 AEDT ]]> Automatic radiotherapy delineation quality assurance on prostate MRI with deep learning in a multicentre clinical trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:43531 Wed 21 Sep 2022 11:32:29 AEST ]]> Real-Time Image Guided Ablative Prostate Cancer Radiation Therapy: Results From the TROG 15.01 SPARK Trial https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:42282 Wed 16 Aug 2023 14:37:30 AEST ]]> Radiotherapy for node-positive prostate cancer: 2019 recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45588 Wed 02 Nov 2022 10:40:43 AEDT ]]> Reduced motion and improved rectal dosimetry through endorectal immobilization for prostate stereotactic body radiotherapy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37462 Wed 02 Mar 2022 14:28:00 AEDT ]]> Rectal protection in prostate stereotactic radiotherapy: a retrospective exploratory analysis of two rectal displacement devices https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31943 P = 0.0012). Comparison (2) demonstrated a moderate difference with centre 2 plans producing slightly lower rectal doses (P = 0.013). Comparison (3) further demonstrated that Rectafix returned lower mean doses than SpaceOAR (P < 0.001). Although all dose levels were in favour of Rectafix, in absolute terms differences were small (2.6-9.0%). Conclusions: In well-selected prostate SBRT patients, Rectafix and SpaceOAR RDD's provide approximately equivalent rectal sparing.]]> Wed 02 Mar 2022 14:25:36 AEDT ]]> Clinical target volume delineation quality assurance for MRI-guided prostate radiotherapy using deep learning with uncertainty estimation https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51626 Tue 12 Sep 2023 15:40:55 AEST ]]> A multi-center prospective study for implementation of an MRI-only prostate treatment planning workflow https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39881 Tue 04 Oct 2022 15:37:28 AEDT ]]> Phase 2 multicenter study of gantry-based stereotactic radiotherapy boost for intermediate and high risk prostate cancer (PROMETHEUS) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34741 Thu 17 Feb 2022 09:29:26 AEDT ]]> FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part I: intact prostate https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:21357 Sat 24 Mar 2018 07:51:27 AEDT ]]> Optimizing radiation therapy quality assurance in clinical trials: a TROG 08.03 RAVES substudy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26274 Sat 24 Mar 2018 07:40:16 AEDT ]]> FROGG high-risk prostate cancer workshop: patterns of practice and literature review: part II post-radical prostatectomy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:28752 Sat 24 Mar 2018 07:37:36 AEDT ]]> Virtual HDR Boost for Prostate Cancer: Rebooting a Classic Treatment Using Modern Tech https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52813 Fri 27 Oct 2023 17:01:02 AEDT ]]> Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52691 Fri 20 Oct 2023 15:54:55 AEDT ]]>